New Directions Targeting Inflammatory and Fibrotic Pathways in the Management of SSc-ILD
Faculty:
Elizabeth R. Volkmann, MD, MS
Assistant Professor of Medicine
Director, UCLA Scleroderma Program
Co-Director, UCLA CTD-ILD Program
Division of Rheumatology
Department of Medicine
University of California, Los Angeles
David Geffen School of Medicine
Los Angeles, CA
Description:
After completing this activity, the participant should be better able to:
- Assess patient risk factors for progressive SSc-ILD
- Describe recommended monitoring for patients with scleroderma and SSc-ILD
- Develop appropriate, evidence-based treatment plans for patients who have SSc-ILD
- Summarize data on emerging agents for the treatment of SSc-ILD
This activity is provided by Paradigm Medical Communications, LLC.
This activity is held in collaboration with the Pulmonary Fibrosis Foundation.